Mohammad Rahbari

机构：German Cancer Research Center, Allameh Tabataba'i University, Heidelberg University, University Children's Hospital Tübingen, University of Tübingen · ORCID：0000-0003-1133-2134

发表论文 65 篇 · 总被引 1189 次 · h-index 16

代表论文

• Targeting Treg–fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma (2025 · Gut · 被引 27)
• Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis (2025 · Nature Genetics · 被引 15)
• Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis (2025 · eLife · 被引 9)
• Activated ATF6α is a hepatic tumour driver restricting immunosurveillance (2026 · Nature · 被引 8)
• Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab (2025 · Journal for ImmunoTherapy of Cancer · 被引 5)
• Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon (2024 · Nature Communications · 被引 5)